silver diamine fluoride
Phase 2- Indications
- Dental caries, Dentinal hypersensitivity
Company intelligence / Profile preview
The company's main product, Advantage Arrest Silver Diamine Fluoride 38%, received FDA clearance in 2014 as a medical device for treating dentinal hypersensitivity. In 2016, it became the first oral care product to receive the FDA's Breakthrough Therapy Designation for arresting tooth decay. Multiple clinical trials have shown efficacy in arresting dental caries. The NIH provided $9.8 million in 2017 to fund a Phase III randomized clinical trial using Advantage Arrest for arresting caries in children.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Advantage Silver Dental Arrest, LLC.